Open-label Randomized Multicenter Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir Boosted Atazanavir to Efavirenz
Overview
- Phase
- Phase 3
- Intervention
- efavirenz
- Conditions
- HIV Infection
- Sponsor
- International Medical Center of Japan
- Enrollment
- 71
- Locations
- 1
- Primary Endpoint
- Antiretroviral effect at the 48th week
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
A selection study in treatment naive HIV patients to compare the virologic success rate of once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and abacavir) plus efavirenz and Epzicom plus ritonavir boosted atazanavir. The superior regimen will be hired to the comparative study to the current first line regimen (tenofovir plus lamivudine plus efavirenz)
Detailed Description
A selection study in treatment naive HIV patients to compare the virologic success rate of once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and abacavir) plus efavirenz and Epzicom plus ritonavir boosted atazanavir. The superior regimen will be hired to the comparative study to the current first line regimen (tenofovir plus lamivudine plus efavirenz) The primary endpoint is antiretroviral effect at the 48th week. The secondary endpoint is;1. Evaluation of immunological effect and safety in 48 weeks. 2.Evaluation of antiretroviral effect, immunological effect and safety in 49 to 96 weeks.
Investigators
Shinichi Oka, M.D.
Director general, AIDS Clinical Center
International Medical Center of Japan
Eligibility Criteria
Inclusion Criteria
- •serological diagnosis of HIV infection
- •male aged over 20 years old
- •CD4 at enrollment between 100 to 300
- •body weight over 40kg
- •enable to obtain the written informed consent
Exclusion Criteria
- •Patients who are considered unable to complete 48 weeks of study by their physician.
- •Patients who have gastrointestinal symptom which may interfere the absorption of antiretrovirals, or have swallowing problems.
- •Patients who have the history of hypersensitivity with lamivudine.
- •Hepatitis B carrier.
- •Blood test results within 4 weeks prior to the randomization; hemoglobin less than 9g/dl, platelet less than 50,000/mm3, neutrophils less than 1000/mm3, serum total bilirubin more than 2.0mg/dl, GOT/GPT/LDH more than two times of upper normal limit, serum creatinine more than 1.2mg/dl.
- •Patients who have had radiation or chemotherapy within 4 weeks prior to the randomization or will have the treatment during the study .
- •Patients who have had immunomodulating agent such as systemic use of corticosteroid or interferon within 4 weeks prior to the randomization. Inhaled corticosteroid is the exception.
- •Patients who have diabetes, congestive heart failure, cardiomyopathy, or other serious medical condition.
- •Patients with AIDS defining illness.
- •Patients with known resistant strains to efavirenz, atazanavir, ritonavir, lamivudine and abacavir prior to the study.
Arms & Interventions
efavirenz arm
Patients are treated with efavirenz 300mg along with Epzicom.
Intervention: efavirenz
atazanavir arm
Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
Intervention: atazanavir arm
Outcomes
Primary Outcomes
Antiretroviral effect at the 48th week
Time Frame: 48 weeks
Secondary Outcomes
- 1. Evaluation of immunological effect and safety in 48 weeks.(48 weeks)
- 2.Evaluation of antiretroviral effect, immunological effect and safety in 49 to 96 weeks.(96 weeks)